TrialLancet (London, England)2019

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.

Harry G M Heijerman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.